DFAC vs IBB
Dimensional US Core Equity 2 ETF vs iShares Biotechnology ETF
- • DFAC has the lower expense ratio at 0.17% vs 0.44% for IBB.
- • DFAC pays a higher dividend yield (0.91%).
Side-by-side metrics
| Metric | DFAC | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.17% | 0.44% |
Dividend yield Trailing 12-month yield. | 0.91% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $47.40B | $9.09B |
YTD return | 11.80% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.99 | 0.69 |
P/E ratio | 23.37 | 24.89 |
Last price | $44.44 | $197.34 |
Inception | — | — |
Issuer | Dimensional | iShares |
DFAC top holdings
| NVDA | NVIDIA Corp | 5.22% |
| AAPL | Apple Inc | 4.83% |
| MSFT | Microsoft Corp | 3.53% |
| AMZN | Amazon.com Inc | 2.74% |
| META | Meta Platforms Inc Class A | 1.76% |
| GOOGL | Alphabet Inc Class A | 1.71% |
| MU | Micron Technology Inc | 1.54% |
| LLY | Eli Lilly and Co | 1.10% |
| GOOG | Alphabet Inc Class C | 1.08% |
| JPM | JPMorgan Chase & Co | 1.02% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About DFAC
DFAC (Dimensional US Core Equity 2 ETF) is Broad US equity market with small and value tilts. Managed by Dimensional, the fund carries $47.4B in assets under management, an expense ratio of 0.17%, a dividend yield of 0.91%. Its largest holding is NVIDIA Corp (NVDA), which represents 5.2% of the portfolio. Real Estate is the fund's largest sector exposure at 0.2%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.